清廉中国
六龙回日Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in vere haemophilia A 期刊名称： Thrombosis & Haemostasis
狮子狗连招作者： Mahlangu, Johnny,Ragni, Margaret,Gupta, Naresh,Rangarajan,
Savita,Klamroth, Robert,Oldenburg, Johannes,Nogami, Keiji,Young, Guy,Cristiano, Lynda,Dong, Yingwen,Allen, Geoffrey,Pierce, Glenn,Robinson, Brian
年份： 2016年
续保话术>中分发型
期号： 第07期
关键词： Pha 3 trial;factor VIII;haemophilia A;haemostasis;surgery
春朱自清朗诵
摘要：The Pha 3 A-LONG and Kids A-LONG studies demonstrated the prolonged half-life of rFVIIIFc compared with rFVIII, and the safety and efficacy of rFVIIIFc in subjects with vere haemophilia A. Eligible subjects from A-LONG and Kids A-LONG continued rFVIIIFc treatment by enrolling in ASPIRE, an ongoing extension study. Bad on combined data from the primary studies an
d ASPIRE interim data, the safety and efficacy of rFVIIIFc in subjects requiring surgery were evaluated. Perioperative dosing regimens were determined by investigators with guidance bad on pharmacokinetic data and recommendations from a clinical dosing committee. In addition to dosing frequency, factor consumption, blood loss, transfusions, bleeding episodes, and haemostatic respon were assd. Across studies, 21 subjects underwent 23 evaluable major surgeries,...
内容由中国教育图书进出口有限公司引进注册投资公司
会计自荐信
